TY - JOUR
T1 - Clinical use of mood stabilizers with antidepressants in Asia
T2 - Report from the research on asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013
AU - Rajaratnam, Kamini
AU - Xiang, Yu Tao
AU - Tripathi, Adarsh
AU - Chiu, Helen F.K.
AU - Si, Tian Mei
AU - Chee, Kok Yoon
AU - Avasthi, Ajit
AU - Grover, Sandeep
AU - Chong, Mian Yoon
AU - Kuga, Hironori
AU - Kanba, Shigenobu
AU - He, Yan Ling
AU - Lee, Min-Soo
AU - Yang, Shu Yu
AU - Udomratn, Pichet
AU - Kallivayalil, Roy A.
AU - Tanra, Andi J.
AU - Maramis, Margarita M.
AU - Shen, Winston W.
AU - Sartorius, Norman
AU - Kua, Ee Heok
AU - Tan, Chay Hoon
AU - Mahendran, Rathi
AU - Shinfuku, Naotaka
AU - Sum, Min Yi
AU - Baldessarini, Ross J.
AU - Sim, Kang
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Objective As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. Methods This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling. Results Use of MS + AD increased by 104% (5.5% to 11.2%) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose. Conclusions The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.
AB - Objective As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. Methods This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling. Results Use of MS + AD increased by 104% (5.5% to 11.2%) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose. Conclusions The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.
KW - antidepressant
KW - anxiety
KW - bipolar disorder
KW - major depression
KW - mood stabilizer
UR - http://www.scopus.com/inward/record.url?scp=85011317364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011317364&partnerID=8YFLogxK
U2 - 10.1097/JCP.0000000000000670
DO - 10.1097/JCP.0000000000000670
M3 - Article
C2 - 28146001
AN - SCOPUS:85011317364
SN - 0271-0749
VL - 37
SP - 255
EP - 259
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 2
ER -
